SP-624

Sirtsei Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SP-624
Sponsor	Sirtsei Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression (PHASE1)
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder (PHASE2)
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder (PHASE2)
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SP-624 CI brief — competitive landscape report
SP-624 updates RSS · CI watch RSS
Sirtsei Pharmaceuticals, Inc. portfolio CI